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CD4/CD25 Regulatory Cells Inhibit Activation of
Tumor-Primed CD4 T Cells with IFN--Dependent
Antiangiogenic Activity, as well as Long-Lasting Tumor
Immunity Elicited by Peptide Vaccination1
Noelia Casares, Laura Arribillaga, Pablo Sarobe, Javier Dotor, Ascensio´n Lopez-Diaz de Cerio,
Ignacio Melero, Jesu´s Prieto, Francisco Borra´s-Cuesta, and Juan J. Lasarte2
CD25 regulatory T (T reg) cells suppress the activation/proliferation of other CD4 or CD8 T cells in vitro. Also, down-
regulation of CD25 T reg cells enhance antitumor immune responses. In this study, we show that depletion of CD25 T reg cells
allows the host to induce both CD4 and CD8 antitumoral responses following tumor challenge. Simultaneous depletion of
CD25 and CD8 cells, as well as adoptive transfer experiments, revealed that tumor-specific CD4 T cells, which emerged in the
absence of CD25 T reg cells, were able to reject CT26 colon cancer cells, a MHC class II-negative tumor. The antitumoral effect
mediated by CD4 T cells was dependent on IFN- production, which exerted a potent antiangiogenic activity. The capacity of
the host to mount this antitumor response is lost once the number of CD25 T reg cells is restored over time. However, CD25
T reg cell depletion before immunization with AH1 (a cytotoxic T cell determinant from CT26 tumor cells) permits the induction
of a long-lasting antitumoral immune response, not observed if immunization is conducted in the presence of regulatory cells. A
study of the effect of different levels of depletion of CD25 T reg cells before immunization with the peptide AH1 alone, or in
combination with a Th determinant, unraveled that Th cells play an important role in overcoming the suppressive effect of CD25
T reg on the induction of long-lasting cellular immune responses. The Journal of Immunology, 2003, 171: 5931–5939.
R egulatory T (T reg)3 cells have a key role in the mainte-nance of immune tolerance to both self- and foreign Ags.In particular, a minor population (10%) of CD4 T cells,
which coexpresses the IL-2R -chain (CD25), has been described
to be crucial for the control of autoreactive T cells in vivo (re-
viewed in Ref. 1). Thus, it has been shown that upon Ag stimu-
lation, this CD4/CD25 cell population potently suppresses the
activation/proliferation of other CD4 or CD8 cells in vitro (2,
3). The mechanism of suppression seems to be the inhibition of
IL-2 transcription in the effector populations. Indeed, suppression
can be abrogated by the addition of exogenous IL-2 or by enhanc-
ing endogenous IL-2 production by means of anti-CD28 Ab (4).
However, the exact mechanism by which CD25 T reg cells exert
their suppressive effects remains unknown. Although some re-
search groups have reported the need of cell-to-cell contact be-
tween suppressor and responder cells to exert the inhibitory func-
tion (3, 5) and that secreted cytokines are not required (6), other
groups have reported that the suppressive effect of CD25 T reg
cells is mediated by soluble factors and do not require cell-to-cell
contact (7, 8).
T cell-mediated immunotherapy represents a promising treat-
ment for cancer. The absence of efficient tumor-specific immune
responses in cancer patients can be related to a deficient APC
function or to T cell tolerance/ignorance toward tumor Ags (9, 10).
It has been postulated that CD4/CD25 immunoregulatory cells
may be engaged in continuously up-regulating the activation
thresholds of other T cells, thereby avoiding effective generation of
tumor immunity while inhibiting autoimmunity (2, 3, 11, 12).
Thus, breaking immunological tolerance may allow effective in-
duction of tumor immunity. Several reports have documented the
potential role of CD25 T reg removal for the induction of tumor
rejection (4, 13–15). Also, depletion of CD25 T reg cells leads to
the activation of otherwise silent tumor-specific CD8 cells (4, 13,
14) as well as tumor-nonspecific CD4CD8 NK-like effector
cells (4). In addition, recent publications have documented that
CD25 T reg cells may contribute to the control of memory CD8
T cell responses (16, 17). These reports suggest that inhibition of
CD25 T reg cell action might have a beneficial effect on the
induction of antitumor immunity when combined with different
strategies of vaccination.
In this work, we have investigated the effect of in vivo admin-
istration of anti-CD25 mAb on the induction of antitumor CD4
and CD8 T cell responses against the BALB/c colon cancer CT26
(18). We have also tested the efficacy of CD25 cell depletion in
combination with peptide vaccination protocols using a cytotoxic
T cell determinant (TCd) (18) and Th cell determinants (THd)
(19), both of them derived from the sequence of murine leukemia
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virus (MuLV) gp70 envelope protein that is a tumor rejection Ag
expressed by CT26. We have found that removal of CD25 cells
permits the induction of both CD4 and CD8 antitumor T cells
in response to CT26 tumor challenge. Interestingly, we have found
that the induced CD4 T cells are able to reject CT26 cells, an
MHC class II-negative tumor. The mechanism of action of these
CD4 cells is mediated by IFN- production which exerts anti-
angiogenic effects. In addition, we have found that CD25 cell
depletion favors the induction of antitumor memory T cell re-
sponses after vaccination with TCd and THd peptides. In the
present study, we analyze the capacity of activated Th cells to
overcome the suppressive effect of CD25 T reg on the induction
of long-lasting cellular immune responses.
Materials and Methods
Peptides
Peptide SPSYVYHQF (from now on AH1) containing a TCd expressed by
CT26 cells and presented by H-2Ld MHC class I molecules (18) and
LVQFIKDRISVVQA (from now on p320–333) containing a Th epitope
(19) for BALB/c MHC class II background, both derived from MuLV gp70
envelope protein, were synthesized by the solid phase method of Merrifield
(20) using a manual multiple solid-phase peptide synthesizer as described
in Ref. 21. At the end of the synthesis, peptides were cleaved, deprotected, and
washed six times with diethyl ether. They were lyophilized and analyzed by
HPLC. The purity of peptides was above 80% as judged by HPLC.
Mice
Six-week-old female BALB/c mice were purchased from IFFA Credo
(Barcelona, Spain). A breeding pair of RAG2/ (mice deficient in T and
B cells) with BALB/c background was obtained from The Jackson Labo-
ratory (Bar Harbor, ME), and were bred and maintained in pathogen-free
conditions. Mouse experimentation followed institutional guidelines and
was approved by the intrainstitutional ethical committee.
In vivo depletion experiments
In vivo depletion of CD25 cells was conducted by i.p. injection of 0.3 mg
of anti-CD25 Abs (obtained from rat anti-mouse hybridoma PC61 (Amer-
ican Type Culture Collection, Manassas, VA) and purified as previously
described (22)), 4 days before tumor challenge. In some experiments, dif-
ferent doses of anti-CD25 mAb were used to obtain partial depletions. In
some experiments, mice were depleted of CD4 and/or CD8 cells by i.p.
injection of 0.3 mg of anti-CD4 and/or anti-CD8 Abs (obtained from rat
anti-mouse hybridomas GK 1.5 and H35.17.2, respectively) on days1, 0,
1, 6, and 10, as previously described (22), day 0 being the day of peptide
immunization. The efficiency of depletions at the day of tumor challenge
was assessed by flow cytometry using PBMC isolated from fresh heparin-
ized blood samples by Ficoll-Hypaque centrifugation. In all cases, the lev-
els of depletion were higher than 95%. Depletion of NK cells was con-
ducted by i.p. administration of rabbit anti-Asialo GM1 antiserum (Wako,
Neuss, Germany) using 100 g per dose on days 2, 1, and 3 after
challenge with CT26 tumor cells. The efficiency of NK depletions was
assessed, at the day of tumor challenge, by flow cytometry using anti CD3
and anti-DX5 Abs. Depletion of CD3/DX5 cells was in all cases above
95%. Also, the efficiency of NK depletion was assessed by measuring the
remaining lytic activity of spleen cells 3 days after a single injection of
rabbit anti-Asialo GM1 antiserum. This was done using Yac-1 cells (Amer-
ican Type Culture Collection) as target cells in a conventional 51Cr release
assay (23). A single injection with 100 g of Ab was able to completely
abrogate NK activity (not shown).
Adoptive T cell transfer experiments
CD4 cells were purified from naive mice or from CD25 and CD8 T
cell-depleted mice by positive selection using anti-CD4 mAb coated to
magnetic beads (Dynal Biotech, Oslo, Norway). Briefly, spleen cells from
normal BALB/c mice were incubated with anti-CD4 coated Dynabeads for
1 h at 4°C following manufacturer’s instructions. After positive selection
using a magnetic concentrator, beads were removed by using DETACHa-
BEAD (Dynal Biotech). After two washes in PBS, cells were counted and
used for adoptive transfer experiments. In some experiments, CD4/
CD25 cells were purified from a CD4-enriched cell preparation obtained
from naive mice, by incubation of cells with anti-CD25 mAb followed by
positive selection using anti-IgG-coated Dynabeads according to manufac-
turer’s instructions (Dynal Biotech). After detachment of beads by over-
night incubation at 37°C, cells were washed and counted for adoptive trans-
fer experiments.
Tumor challenge experiments
To measure the antitumoral capacity of the different treatments and/or im-
munization protocols, mice were challenged by s.c. injection on the right
flank with 5  105 CT26 tumor cells at different time points. In some
experiments animals were immunized with different combinations of pep-
tides in IFA (Difco, Detroit, MI) or IFA alone as described previously (19).
Tumor size was expressed as the square value of the small diameter of the
tumor, times the value of its larger diameter. Mice were sacrificed when
tumor size reached a volume greater than 8 cm3.
Recognition of CT26 tumor cell lysate by CD4 T cells from
mice exposed to CT26 tumor cells
The presence of antitumoral CD4 cells was measured in mice 30 days
after challenge with CT26 tumor cells. CD4 T cells were purified from
naive mice or from mice previously depleted from CD25 and CD8 cells
as described above and stimulated in vitro (2  105 CD4 cells/well and
4  105 mitomycin-treated spleen cells/well from naive mice) with or
without different dilutions of cell extracts from CT26, MC38, P815, A20,
NS1, or 18Neo cells. To obtain cell extracts, 107 tumor cells or 18Neo
cells/ml were lysed by six cycles of freezing and thawing followed by
sonication and centrifugation. CT26 colon cancer, MC38 adenocarcinoma,
P815mastocytoma, A20 lymphoma, and NS1 myeloma cells were obtained
from the ATCC collection (American Type Culture Collection). 18Neo
cells are derived from NIH 3T3 cells and were kindly provided by Dr. J.
Berzofsky (National Institutes of Health, Bethesda, MD). Culture super-
natants were collected after 48 h of culture to measure production of IFN-
by using a commercial ELISA kit (BD PharMingen, San Diego, CA) ac-
cording to the manufacturer’s instructions. Cell proliferation was assayed
after 3 days of culture by measuring [methyl-3H]thymidine incorporation.
Briefly, the second day of culture 0.5 Ci [methyl-3H]thymidine were
added to each well and incubated overnight. Cells were harvested (Filter-
mate 196 harvester; Packard Instrument, Meriden, CT) and incorporated
radioactivity was measured using a scintillation counter (Topcount; Pack-
ard Instrument).
PCR primers and RT-PCR
Cell extracts from CT26, MC38, P815, A20, NS1, or 18Neo cells were
obtained as described above. Total RNA was isolated from cell extracts
using Ultraspect RNA isolation kit (Biotex, Houston, TX) following man-
ufacturer’s instructions. One microgram of RNA was reverse-transcribed
as previously described (24) and the cDNA was amplified with Taq poly-
merase using specific primers for MuLV gp70 env (sense primer: ACCT
TGTCCGAAGTGACCG, antisense primer: GTACCAATCCTGTGTG
GTCG, to amplify a 594-bp fragment as described (18)) or for -actin
(sense primer: TCTACAATGAGCTGCGTGTG, antisense primer: GGT
GAGGATCTTCATGAGGT, to amplify a 314-bp fragment as described
(24)). Amplified cDNA was electrophoresed through 1% agarose and vi-
sualized under UV after ethidium bromide staining.
Matrigel angiogenesis assay
Angiogenesis assays were conducted by injecting 0.3 ml of ice-cold Ma-
trigel (Collaborative Biomedical Products, Bedford, MA) containing 10
ng/ml vascular endothelial growth factor and 10 ng/ml basic fibroblast
growth factor (Peprotech, London, U.K.) mixed with 5  105 CT26 cells
to BALB/c mice: 1) untreated; 2) depleted of CD25 and CD8 T cells, 3)
depleted of CD25 and CD4 T cells. To study the effect of IFN- on
angiogenesis, two subgroups of mice, depleted of CD25 and CD8 T
cells or depleted of CD25 and CD4 cells, were injected with anti-IFN-
Abs at days 0, 2, and 5 after matrigel implantation (n  6 in all groups).
Matrigel injections were performed s.c. on the right flank of the mice. Nine
days after implantation, plugs were harvested, surrounding tissue was dis-
sected away, and the pellets were liquefied by incubation at 4°C overnight
in 300 l of PBS. The remaining pellets were further disrupted using a
mechanic homogenizer. Hemoglobin content was quantified by measuring
absorbance of the samples at 410 nm and by comparing with the absor-
bance of standard hemoglobin solutions.
Statistics
Statistical analysis was conducted using the computer program SPSS for
Windows (Chicago, IL). Evaluation of the antiangiogenic effect of CD25
and CD8 cell depletion and the differences in the IFN- production be-
tween groups were done using the Shapiro-Wilk test followed by the
Dunnett test.
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Results
Effect of in vivo depletion of CD25, CD4, or CD8 cells on
the protection against CT26 tumor challenge
Immunization of BALB/c mice with AH1 (a TCd expressed by
CT26 cells) is unable to induce a protective CTL response against
challenge with CT26 tumor cells (18). This is due to the inability
of AH1 to induce a competent Th response (19). However, when
mice were depleted of CD4 cells, immunization with AH1 pro-
tected all animals from tumor challenge (Ref. 19 and Table I),
paradoxically suggesting that CD4 T cells were not necessary, or
might even be detrimental for the induction of CTL responses.
This made us think that elimination of CD4/CD25 regulatory
cells might be at the origin of this result. To study whether the
protective effect of immunization with AH1, in mice depleted of
CD4 cells, was mediated by the elimination of CD4/CD25
cells, we selectively depleted this subpopulation by i.p. injection of
anti-CD25 Abs previous to challenge with CT26 tumor cells. The
efficiency of this depletion was in all cases above 95% (not
shown), as assessed by flow cytometry. It was found that CD25
cell depletion led to a full protection (6 of 6 mice) against tumor
challenge (Table II). Interestingly, and in contrast to what was
found in CD4 cell-depleted mice, the protection observed after
depletion of CD25 cells did not require immunization with AH1.
Thus, all CD25 depleted and nonimmunized mice remained pro-
tected against CT26 tumor challenge, whereas all CD4-depleted
and nonimmunized mice developed tumors (compare Tables I
and II).
To confirm the inhibitory role of CD25 cells on the induction
of a protective cellular immune response against CT26 tumor cell
challenge, we conducted adoptive transfer of CD25 cells. Thus,
the same day of challenge with CT26 tumor cells, we infused 5 
106 CD25 cells (obtained from naive mice) to AH1-immunized
animals, which had been depleted of CD4 cells. It was found that
adoptive transfer of CD25 cells abrogated the protective effect
observed following immunization of CD4 cell-depleted mice
with AH1 (Table III). This result suggests that at least in this
model, CD25 cells are the main inhibitors for the induction of
antitumoral immune responses.
CD4 and CD8 cells are the main effector cells for the
protection against CT26 tumor challenge after depletion of
CD25 cells
To identify the subpopulations of cells responsible for the protec-
tion against CT26 tumor grafting in mice depleted of CD25 cells,
we conducted the following experiments of combined cell deple-
tion previous to tumor challenge: 1) CD25 and CD4, 2) CD25
and CD8, 3) CD25 and CD4 and CD8, and 4) CD25 and
NK cells. It was found that depletion of CD4 cells in mice de-
pleted of CD25 had a negative effect on protection against tumor
challenge. Thus, only 4 of 12 mice (33%) remained free of tumors
after this combined depletion. Similarly, depletion of CD25 and
CD8 cells had a negative effect on protection, only 11 of 20 mice
(55%) remained protected (Fig. 1). By contrast, protection after
combined depletion of NK and CD25 cells was similar to that
found in mice depleted of CD25 T cells only. Combined deple-
tion of CD25, CD4, and CD8 cells, completely abrogated pro-
tection (6 of 6 mice developed tumors) indicating that T cells are
responsible for protection after depletion of CD25 cells.
Interestingly, 55% of mice remained protected after combined
depletion of CD8 and CD25 cells. This result suggests that
CD4 cells by themselves were able to protect mice against chal-
lenge with CT26 tumor cells, a tumor which does not expresses
MHC class II molecules.
CD4 cells, induced in the absence of CD25 and CD8 cells,
produce IFN- in response to CT26 tumor Ags
As shown in Fig. 1, 55% of mice depleted of CD25 and CD8
cells remained free of tumor after challenge with CT26 tumor
cells. However, combined depletion of CD25, CD8, and CD4
cells completely abrogated protection suggesting that in the first
case, protection is mediated by CD4 cells. This fact prompted us
to study the capacity of CD4 cells, induced in the absence of
CD25 and CD8 cells, to respond to CT26 tumor Ags. For this
purpose, we purified CD4 cells from: 1) nonprotected undepleted
mice (control group); 2) from CD25 and CD8 cell-depleted
mice that remained protected after CT26 tumor challenge, and 3)
from CD25 and CD8 depleted mice that developed tumors after
CT26 tumor challenge. Cells from these three groups were cul-
tured for 48 h in the presence of cell extracts from CT26 or 18Neo
cells (see Materials and Methods) and the production of IFN-
was measured by ELISA.
Table III. Effect of CD4 cell depletion and adoptive transfer of
CD25 cells on the protection after challenge with CT26 tumor cells
Immunized
with
In Vivo Treatment
Mice
ProtectedaDepletion Adoptive transfer
AH1 Anti-CD4b None 7/7
AH1 Anti-CD4 CD25 cellsc 2/7
AH1 None None 0/7
IFA None None 0/7
a Mice were challenged at day 11 after immunization. Percentage of protection
was determined 30 days after CT26 challenge. Similar results were obtained in two
independent experiments.
b CD4 cell depletion was carried out by i.p. injection of anti-CD4 mAbs at days
3, 2, and 1, day 0 being the day of immunization.
c Adoptive transfer of CD25 cells from naive BALB/c mice was carried out at
day 9 after immunization.
Table I. Effect of CD4 and CD8 cell depletion on the protection
after challenge with CT26 tumor cells
Immunized with In Vivo Treatmenta Mice Protectedb
AH1 None 0/6
Anti-CD4 6/6
Anti-CD8 0/6
None Anti-CD4 0/6
Anti-CD8 0/6
a Depletion of CD4 or CD8 cells was carried out by i.p. injection of anti-CD4
or anti-CD8 mAbs at days 3, 2, and 1, day 0 being the day of immunization.
b Mice were challenged with CT26 tumor cells at day 10 after immunization.
Percentage of protection was calculated 30 days after challenge with CT26 tumor
cells. Similar results were obtained in two independent experiments.
Table II. Effect of CD25 cell depletion on the protection after
challenge with CT26 tumor cells
Immunized with In Vivo Treatmenta Mice Protectedb
AH1 Anti-CD25 6/6
None Anti-CD25 6/6
AH1 None 0/6
None None 0/6
a Depletion of CD25 cells was carried out by i.p. injection of anti-CD25 mAbs
at day 4, day 0 being the day of immunization.
b Mice were challenged with CT26 tumor cells at day 10 after immunization.
Percentage of protection was calculated 30 days after challenge with CT26 tumor
cells. Similar results were obtained in three independent experiments.
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As shown in Fig. 2A, CD4 cells, from CD25 and CD8
depleted mice that remained protected after CT26 tumor challenge,
produce high levels of IFN- in response to extracts from CT26
tumor cells. These levels were higher than those produced by
CD4 cells from unprotected mice depleted of CD25 and CD8
cells (group 3), or from CD4 cells from naive mice (group 1)
( p  0.05). These results suggest that CD4 T cells, induced after
depletion of CD25 cells, are specific of tumor Ags. To study the
specificity of activated CD4 T cells, a group of CD25 and
CD8 cell-depleted mice (n  5), which remained protected after
CT26 tumor challenge, were rechallenged s.c. with 5  105 cells
from a different tumor (A20). This new challenge was conducted
45 days after depletion of CD25 cells, when this subpopulation
had reached normal levels. It was found that 4 of 5 mice (as op-
posed to 0 of 5 from the control group) rejected this second chal-
lenge with A20 lymphoma. We also measured proliferation of
CD4 T cells (from the different groups of mice) in response to
cell extracts from CT26, MC38, P815, A20, NS1 tumor cells as
well as from 18 Neo cells. For this purpose, 30 days after CT26
challenge, CD4 T cells were isolated from the following groups:
1) mice depleted of CD25 cells (all protected from tumor chal-
lenge); 2) mice depleted of CD25 and CD8 T cells, which re-
mained protected after tumor challenge; 3) mice depleted of
CD25 and CD8T cells, which developed tumors after CT26
challenge, and 4) from undepleted unprotected mice. As shown in
Fig. 2B, CD4T cells from mice from groups 1 and 2, were able
to proliferate in response to all the cell extracts tested, whereas
CD4 T cells from groups 3 and 4 were not. However, the pro-
liferative response of CD4T cells to the cell extracts was depen-
dent on the cell extract tested. Thus, it was found that response to
CT26, MC38, A20 and NS1 was significantly higher that that ob-
served for P815 or 18Neo ( p  0.05). Because the MuLV gp70
env transcript is expressed in a variety of tumor cells and has been
described as a tumor Ag (18, 25–27), we tested the presence of
gp70 RNA transcripts in the different cell lines by RT-PCR. As
shown in Fig. 2B (upper panels), MuLV gp70 env is expressed by
CT26, MC38, A20, and to a lesser extend by P815 cells. We were
unable to detect MuLV env expression in NS1 cells, despite the
capacity of CD4T cells to proliferate in response to tumor ex-
tracts from NS1. These data suggest that MuLVgp70 is not the
only source of the determinants recognized by such antitumor
CD4 T cells.
Protective effect of adoptive transfer of CD4 cells obtained
from mice depleted of CD25 and CD8 cells: role of IFN-
To study the antitumoral effect of these CD4 cells, we isolated
CD4 cells from mice depleted of CD25 and CD8 cells which
remained protected after CT26 tumor challenge as well as from
those mice which developed tumors. CD4 cells from these two
FIGURE 1. Antitumoral effect of CD4, CD8, or NK cells, induced in
the absence of CD25 cells. Groups of mice were depleted of: CD25;
CD25 and CD8; CD25 and CD4; CD25, CD4, and CD8; CD25
and NK cells; or nondepleted. Mice were challenged with CT26 tumor cells
following cell depletion. Tumor size was measured 30 days after tumor
challenge. Values correspond to tumor size from each mouse and they were
calculated as the square value of the small diameter of the tumor, times the
value of the larger diameter.
FIGURE 2. IFN- production by purified CD4 cells obtained from different groups of mice after challenge with CT26 tumor cells. A, Naive undepleted
mice (n  5), or mice depleted of CD8 and CD25 cells (n  5), were challenged with CT26 tumor cells. Thirty days after challenge, CD4 cells from
undepleted nonprotected naive mice (control group), as well as from protected or nonprotected mice from the depleted group, were cultured in the presence
of extracts from CT26 or 18Neo cells (see Materials and Methods). After 48 h of culture, IFN- was measured by ELISA in the culture supernatants. B,
Upper panels, Levels of expression of MuLV gp70 by different cell lines as measured by RT-PCR. Bottom panel, Proliferation of CD4 T cells from
different groups of mice in response to cell extracts from CT26, MC38, P815, A20, NS1, or 10Neo cells. Mice were depleted of CD25 cells only; of
CD25 and CD8 cells; or nondepleted. All groups were challenged with CT26 tumor cells. Thirty days after challenge, proliferation of CD4 cells was
measured in response to the different tumor cell extracts (see Materials and Methods). As indicated, mice from the group CD25 and CD8 cells are
classified as protected or nonprotected depending on the presence or absence of tumors (n  5 in all groups). , A significant difference in proliferation
(p  0.05) with respect to the control 18Neo cell extract.
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groups were adoptively transferred (107 cells/mice) to BALB/c
mice previously depleted from CD8 cells. As control, a group of
mice depleted of CD8 was injected with saline. The same day of
cell infusion, mice were challenged with 5  105 CT26 tumor
cells. The evolution of tumors was assessed 30 days after. As
shown in Table IV, two of the three mice depleted of CD8 cells
that were adoptively transferred with CD4 cells from protected
mice remained free of tumors, whereas all the mice infused with
CD4 cells from unprotected mice or with saline developed tu-
mors. To expand and reinforce these results in a slightly different
setting, we adoptively transferred these antitumor CD4 cells in
RAG2/ mice. Three groups of RAG2/ mice were adoptively
transferred with: 1) antitumor CD4 cells (seven mice) obtained
from mice depleted of CD25 and CD8 cells which remained
protected after CT26 tumor challenge; 2) CD4 cells from naive
mice (five mice) and 3) with saline only (three mice), the same day
of CT26 tumor challenge. As shown in Table V, 5 of 7 mice
infused with antitumor CD4 cells remained free of tumors (71%
of protection) whereas only 1 of 5 mice infused with CD4 cells
from naive mice was protected (20% of protection). None of the
mice injected with saline were protected (0% of protection). To
study the possible role of IFN- on this protective effect, a group
of RAG2/ mice adoptively transferred with antitumor CD4
cells (n  4) was treated at days 0, 2, and 4 after CT26 tumor
challenge, with three i.p. injections of 100 l of ascitic fluid con-
taining neutralizing anti-IFN- Abs. This treatment completely ab-
rogated the protective effect of adoptive transfer of antitumor
CD4 cells (4 of 4 mice developed tumors) (Table V).
Secretion of IFN- inhibits tumor angiogenesis
As shown in Fig. 3, CD4 cells induced in the absence of CD25
and CD8 cells, produce IFN- in response to CT26 tumor ex-
tracts. Because it has been recently described that CD4 T cells
can inhibit tumor growth by inhibiting tumor angiogenesis, and
that this inhibition is IFN--dependent (28, 29), we conducted in
vivo matrigel assays to measure the extent of angiogenesis stim-
ulated by CT26 cells in the following groups of six mice: 1) mice
doubly depleted of CD25 and CD8, 2) mice doubly depleted of
CD25 and CD8 and treated with anti-IFN- Abs, 3) mice dou-
bly depleted of CD25 and CD4, 4) mice doubly depleted of
CD25 and CD4 and treated with anti-IFN- Abs, and 5) unde-
pleted mice. All five groups of mice were injected with matrigel
containing CT26 cells as described in Materials and Methods.
Hemoglobin content of the matrigel plugs was quantified 9 days
after implantation and this value was used as a measure of tumor
angiogenesis. As shown in Fig. 3, depletion of CD25 and CD8
cells significantly reduces angiogenesis induced by CT26 embed-
ded in matrigel ( p  0.001). This inhibition is mediated by IFN-
production because injection of Abs against IFN- is able to re-
store the levels of angiogenesis observed in nondepleted mice.
However, double depletion of CD25 and CD4 cells did not
have any effect on angiogenesis, suggesting that the main group of
cells responsible for the observed antiangiogenic effect were
CD4 T cells induced in the absence of CD25 cells.
Depletion of CD25 cells facilitates the induction of antitumor
memory T cell responses after peptide vaccination
As described above, depletion of CD25 cells allows mice to in-
duce a protective T cell immune response against challenge with
CT26 tumor cells. However, this protective effect was observed
when the challenge was done 10 days after depletion of CD25
FIGURE 3. IFN--dependent inhibition of tumor angiogenesis in mice
depleted of CD25 and CD8 cells. Different groups of depleted or non-
depleted mice were injected s.c. with CT26 tumor cells embedded in ma-
trigel as described in Materials and Methods. As indicated, subgroups of
mice depleted of CD25 and CD8 cells or of CD25 and CD4 cells
were injected with anti-IFN- Abs at days 0, 2, and 5 after matrigel im-
plantation. Nine days after implantation, plugs were harvested and hemo-
globin content was used as a measure of angiogenesis (n 6 in all groups).
A similar result was obtained in another independent experiment.
Table IV. Effect of adoptive transfer of CD4 cells (BALB/c)a
Mice
In Vivo Treatment
Mice
ProtectedbAdoptive transfer Depletion
BALB/c CD4 from
protected micec
CD8 depleted 2/3
BALB/c CD4 from not
protected micec
CD8 depleted 0/3
BALB/c Saline CD8 depleted 0/3
a Effect of adoptive transfer of CD4 cells, from CD8 and CD25 depleted
BALB/c mice which remained protected after challenge with CT26 tumor cells, to
BALB/c mice depleted of CD8 cells.
b Mice were challenged with CT26 tumor cells. Percentage of protection was
determined 30 days after challenge. Similar results were obtained in two independent
experiments.
c CD4 cells from CD8 and CD25 cell-depleted BALB/c mice which remained
protected after challenge with CT26 tumor cells were transferred to RAG2/ mice
and treated or nontreated with anti-IFN- Abs. Adoptive transfer was carried out the
same day of challenge with CT26 tumor cells (day 0), whereas treatment with anti-
IFN- Abs was carried out at days 0, 2, and 4 after challenge. As controls, RAG2/
mice were transferred with CD4 cells from naive BALB/c mice or with saline.
Table V. Effect of adoptive transfer of CD4 cells (RAG/)a
Mice
In Vivo Treatmentb
Mice Protectedc
(%)Adoptive transfer Anti-IFN-
RAG/ CD4 cells from
protected miceb
No 5/7 (71.4)
RAG/ CD4 cells from
protected miceb
Yes 0/4 (0)
RAG/ CD4 cells from
naive miceb
No 1/5 (20)
RAG/ Saline No 0/3 (0)
a Effect of adoptive transfer of CD4 cells, from CD8 and CD25 depleted
BALB/c mice which remained protected after challenge with CT26 tumor cells, to
RAG2/ mice.
b CD4 cells from CD8 and CD25 cell-depleted BALB/c mice which remained
protected after challenge with CT26 tumor cells were transferred to RAG2/ mice
and treated or nontreated with anti-IFN- Abs. Adoptive transfer was carried out the
same day of challenge with CT26 tumor cells (day 0), whereas treatment with anti-
IFN- Abs was carried out at days 0, 2, and 4 after challenge. As controls, RAG2/
mice were transferred with CD4 cells from naive BALB/c mice or with saline.
c Mice were challenged with CT26 tumor cells. Percentage of protection was
determined 30 days after challenge. Similar results were obtained in two independent
experiments.
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cells. As described previously, mice depleted of CD25 cells fol-
lowing administration of anti-CD25 mAb Abs recover the normal
level of CD25 cells 35 days after this administration (15, 30). We
then studied whether the protective effect following depletion of
CD25 cells was dependent on the period of time elapsed between
depletion and challenge with CT26 tumor cells. Thus, we injected
CT26 tumor cells at days 10, 20, 40, or 50 after CD25 cell de-
pletion. Protective immunity in response to CT26 tumor cells was
100% when the challenge was conducted at day 10 after depletion.
However, the antitumor efficacy decreases to 50% or to 0% when
the challenge with CT26 cells was performed at days 40 and 50
after depletion, respectively (Table VI).
In a previous work from our group, it was observed that immu-
nization of mice with peptide AH1 (a TCd derived from MuLV
gp70 envelope protein and expressed by CT26 cells (18)), did not
induce a protective CD8 T cell response despite its partial ca-
pacity to delay tumor growth (19). This delay was only observed
if CT26 challenge was conducted 10 days after immunization, be-
ing undetectable if the challenge was done 20 days after immu-
nization (not shown). However, if CD25 T cell-depleted mice
were immunized with AH1 peptide, 83% of mice remained free of
tumors after challenge with CT26 cells, even when the challenge
was conducted 50 days after immunization (Table VI). These re-
sults suggest that the absence of CD25 regulatory cells may im-
prove the efficacy of peptide immunization and the establishment
of a memory T cell response.
In contrast to immunization with AH1 alone, joint immunization
with AH1 and peptide p320–333, a THd peptide derived from
MuLV gp70 envelope protein, is able to induce a protective anti-
tumoral CD8 T cytotoxic cell response against challenge with
CT26 tumor cells (19). However, the protective effect induced by
this joint immunization only lasts a short period of time. Indeed,
we have found a protection of 90% if the challenge with CT26
tumor cells is conducted 10–15 days after immunization (19). By
contrast, the protection decreased to only 0–10% if mice were
challenged 20 days after immunization (not shown). Because
CD25 regulatory cells seemed to play a negative role in the in-
duction of long-term antitumoral responses after immunization
with AH1, we studied the protective effect of immunization of
mice with AH1 alone, or in combination with peptide p320–333,
under different degrees of depletions of CD25 regulatory cells.
Thus, five groups of mice were treated by i.p. injection of 0, 1, 10,
50, and 300 g of anti-CD25 mAb Ab. The levels of depletion
attained were 0  5%, 33.8  7.5%, 66.2  8.4%, 95.5  1.7%,
and 99.3  0.5%, respectively. These groups of mice were immu-
nized with AH1 alone, AH1 plus p320–333 or with IFA only (see
Materials and Methods). Fifty days after immunization, mice were
FIGURE 4. Effect of partial depletion of CD25 cells before peptide vaccination, on the induction of a protective long-lasting antitumoral immune
response. Groups of mice were treated by i.p. injection of 0, 1, 10, 50, and 300 g of anti-CD25 mAb Ab. This afforded depletions of 0  5%, 33.8 
7.5%, 66.2  8.4%, 95.5  1.7%, and 99.3  0.5% CD25 cells, respectively. Mice from these groups were immunized with AH1; AH1 plus p320–333;
or with IFA alone, as described in Materials and Methods. Fifty days after immunization, mice were challenged with CT26 tumor cells and tumor size was
measured 20 days after. A, The tumor size of each individual mouse, immunized under the condition shown, is represented with a dot, whereas in (B) each
point represents the average tumor size from the six mice of each group, plotted against the degree of CD25 cell depletion.
Table VI. Induction of long-lasting protection against challenge with
CT26 tumor cells in mice depleted of CD25 cells and vaccinated with
AH1
Immunized
with
In Vivo
Treatment
Day of Challenge
of CT26a
Percent of
Protection (%)
None Saline 10 0/6 (0)
20 0/6 (0)
40 0/6 (0)
50 0/6 (0)
Anti-CD25 10 6/6 (100)
20 6/6 (100)
40 3/6 (50)
50 0/6 (0)
AH1 Saline 10 0/6 (0)
20 0/6 (0)
40 0/6 (0)
50 0/6 (0)
Anti-CD25 10 6/6 (100)
20 6/6 (100)
40 5/6 (83)
50 5/6 (83)
a Mice were challenged at days 10, 20, 40, or 50 after treatment with saline or with
anti-CD25 mAbs. Similar results were obtained in two separate experiments.
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challenged with CT26 tumor cells and tumor size was measured 20
days after challenge. In Fig. 4A, we represent with a dot the tumor size
in each individual mouse, whereas in Fig. 4B we represent the average
tumor size from each group of mice against the degree of CD25 cell
depletion. As shown, immunization with AH1 alone, or with AH1
plus p320–333, after total depletion of CD25 cells resulted in long-
term protection levels of 83 and 100%, respectively.
It is interesting to note that protection induced by AH1 alone,
requires the complete absence of CD25 cells. Indeed, when mice
were treated with 50 g of anti-CD25 Ab, which depletes 95.5%
of CD25 cells, the remaining cells (4.5%) are still able to inhibit
the induction of a protective cellular immune response. However,
under the same level of depletion of CD25 cells (95.5%), if AH1
was coimmunized with p320–333, a 100% protection was at-
tained. Moreover, when mice treated with 1–10 g of anti-CD25
Abs (depletion levels of 33.8 and 66.2%, respectively) were im-
munized with AH1 plus p320–333 the levels of protection were
33% in both cases. These results suggest that T cell help provided
by p320–333 immunization overcomes, at least partially, the sup-
pressive effect of CD25 regulatory cells.
Discussion
CD4 Th cells play an important role on the induction of CTL (23,
31–34). However, it has also been described that depletion of
CD4 T cells may favor the induction of CTL responses (14, 22,
35), and enhance the therapeutic efficacy in tumor rejection (14,
35) suggesting that CD4 T cells play a regulatory role. These
results are in agreement with our finding that vaccination with
AH1 alone is unable to protect mice from challenge with CT26
tumor cells (18, 19), whereas if this vaccination is conducted after
depletion of CD4 cells, mice are protected. Recent reports have
shown that these CD4 T reg cells express the CD25 marker (3,
11). Also, depletion of CD25 T reg cells with Abs facilitates the
induction of tumor immunity (4, 13–15), a result in agreement with
our finding that mice depleted of CD25 cells are able to reject
CT26 tumor cells and that adoptive transfer of CD25 T cells
abrogates this protection. It is interesting to note that, in contrast to
what is found after depletion of CD4 cells, depletion of CD25
cells permits tumor rejection without the need of a previous vac-
cination with AH1. It could be argued that absence of CD25
regulatory cells enhances the immunogenicity of CT26 tumor cells
by stimulating tumor-specific CD4 Th cells, which are now ca-
pable of providing efficient T cell help for antitumor CTL induc-
tion. However, in the case of complete depletion of CD4 cells,
both T reg and Th cells are depleted. Under this condition, neither
a Th response, nor a concomitant CTL response, can be elicited by
CT26 tumor cells. However, vaccination with peptide AH1 can
bypass the need for T cell help inducing a protective response by
direct activation of CTL when their TCR recognize the complex
AH1-MHC class I complexes at the surface of APCs.
It has been described that the Ab-mediated depletion of CD25
T reg cells facilitates the induction of tumor immunity by favoring
activation of tumor-specific CD8 cells (4, 13, 14) as well as tu-
mor nonspecific CD4CD8 NK-like effector cells (4). In the
present publication, we show that depletion of CD25 cells allows
the induction of both antitumor CD4 and CD8 cells, a result in
agreement with the recent publication by Golgher et al. (30). In-
deed, simultaneous depletion of CD25 and CD8 T cells, or
CD25 and CD4 T cells, but not triple depletion of CD25,
CD4, and CD8 T cells, permits rejection of CT26 tumor cells in
an important number of animals. Combined depletion of NK cells
and CD25 cells did not abrogate protection, suggesting that NK
cells do not play a determinant role in protection.
Many studies, including our own, have described the role of
CD4 T cells in providing help for the induction of CTLs (23,
31–34, 36). However, CD4 T cells can coordinate other antitu-
mor effector pathways independent of CTLs (37). We have found
that CD4 T cells, obtained from mice depleted from CD25 and
CD8 cells that remained protected after CT26 tumor challenge,
produced high amounts of IFN- in response to CT26 tumor Ags
in vitro. However, it was also found that activated CD4 T cells
proliferated, not only in response to extracts from CT26, but also,
in response to extracts from MC38, A20, P815, NS1, and 18Neo
cells. Several interpretations might explain this finding: 1) first,
depletion of CD25 T reg cells might down-regulate the activation
threshold of CD4 T cells specific for Ags from the cell extracts.
In other words, proliferations in response to cell extracts (Fig. 2B)
might be the result of an in vitro induction of T cells by these
extracts, and not of an in vivo induction after challenge with CT26
tumor cells. However, we do not favor this interpretation because
when mice depleted of CD25 and CD8 T cells that rejected
CT26 tumor cells were challenged with a second tumor (A20),
once the level of CD25 T reg cells was restored, these mice
rejected the tumor, a result in agreement with that recently reported
by Golgher et al. (30). 2) A second interpretation might be related
to traces of other Ags from the FBS where CT26 tumor cells are
grown. These Ags would induce a T cell response in vivo that
would be expanded in vitro during the proliferation assays. If this
were the case, a similar level of proliferation should be expected
for all cell extracts. However, because proliferation of CD4 T
cells in response to CT26, MC38, A20, and NS1 cell extracts was
significantly higher than that in response to extracts from P815 or
18Neo cells ( p  0.05), we do not favor this interpretation either.
3) A third possibility might be related to a cross-reaction between
shared Ags. Thus, using RT-PCR, we studied if the gp70 env gene
was an Ag shared by the cell lines used in our study. It was found
that the gp70 gene was expressed in CT26, MC39, A20, and to a
lesser extent in P815 cells, but not in NS1 or in 18Neo cells. Thus,
gp70 alone cannot explain all the differences in proliferation, sug-
gesting that besides gp70, other tumor Ags might be involved in
tumor rejection mediated by CD4 T cells. In summary, although
we favor that the observed proliferation from Fig. 2B is most likely
related to shared Ags between cells, additional experiments are
needed to identify these shared Ags and to establish whether they
are autoantigens shared by normal tissues.
Adoptive transfer of these antitumor CD4 cells, conducted in
the present study using BALB/c mice as well as in RAG2/mice,
demonstrate that these T cells are able to protect mice against
tumor challenge, and that this protective effect is mediated by
IFN-. In agreement with results reported by other research groups
(28, 37, 38). In this study, we show that in the absence of CD25
T reg cells, an IFN--producing antitumor CD4 cell subpopula-
tion emerges in response to tumor cells, exerting potent IFN--
dependent antiangiogenic effects.
Because IFN- has multiple biological activities, and its recep-
tor (IFN-R) is expressed in almost all cell types (39, 40), this
cytokine might have direct effects on tumor cells such as: 1) in-
hibiting cell proliferation or sensitizing cells to apoptosis (41, 42);
2) up-regulating MHC class I expression and thereby increasing
tumor cell lysis (43); 3) up-regulating MHC class II expression on
tumor cells (44, 45), 4) stimulating NK activity (46), or 5) inducing
the expression of angiogenesis inhibitors, like IFN--inducible
protein-10, by tumor and stromal cells (47). We have not found
any inhibitory effect of IFN- on proliferation of CT26 tumor cells
in vitro even at doses of 7500 U/ml (around 3  106 pg/ml) (not
shown). Up-regulation of MHC class I molecules and the suscep-
tibility to CTL-dependent lysis may not be the mechanisms of
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action of IFN- produced by CD4 cells because mice were de-
pleted of CD25 and also of CD8 T cells. Moreover, adoptive
transfer of these CD4 T cells to RAG2/ (mice deficient in T
and B cells) protected against tumor challenge. When we tested the
expression of MHC class II molecules in CT26 cells after incuba-
tion with different concentrations of IFN-, it was found that even
at 2000 IU/ml cytokine, CT26 cells did not acquire detectable
MHC class II expression (not shown). In addition, when we mea-
sured the cytotoxic activity of purified CD4 T cells from pro-
tected mice, against IFN--treated CT26 cells, no activity was
found even at an E:T ratio of 100:1 (not shown). Because alter-
natives 1–4 do not seem to be relevant to explain the protective
effect of IFN- produced by CD4 cells, and as shown in Fig. 3,
IFN- inhibits angiogenesis, we favor the hypothesis that IFN--
dependent antiangiogenic activity may constitute an important ef-
fector mechanism explaining the antitumor activity of these CD4
T cells.
Depletion of CD25 T reg cells per se allows the immune sys-
tem to mount an efficient antitumoral immune response in mice
against tumors that are poorly immunogenic (4, 14, 15, 30). How-
ever, when we conducted tumor challenge 50 days after depletion
of CD25 T cells, once the population of CD25 T reg cells was
restored, all challenged mice developed lethal tumors. Thus, the
beneficial effect of depleting CD25 T reg cells only takes place
shortly after depletion of these cells, when their levels are still very
low, suggesting that vaccination immediately after depletion of
CD25 T reg cells might greatly enhance the ability of the host to
mount a protective antitumoral immune response. This strategy
might even permit to induce antitumoral responses using the class
I epitope only, because as shown in our work, a single adminis-
tration of anti-CD25 mAb before immunization with AH1 permits
the induction of a long-lasting protective antitumor immune re-
sponse (83% of protection). However, in the absence of depletion
of CD25 cells, AH1 is unable to induce a protective response
against challenge with CT26 tumor cells (18) due to the incapacity
of this peptide to induce a competent Th response (19). Our results
are in accordance with two recent publications suggesting that the
presence of CD4/CD25 cells may restrict or control memory T
cell responses (16, 17). In addition to the results reported by Kur-
sar et al. (16), we show in this study that depletion of CD25 T
cells, previous to a single immunization (priming immunization),
permits peptide vaccination to induce a protective long-lasting an-
titumoral effect which is not observed in the presence of CD25
reg cells. We are aware that maintaining a CD25 T reg-depleted
status for a long period of time, may have the risk of developing
autoimmunity (48–50). Also, depletion of T cells expressing the
CD25 marker would not only eliminate T reg cells, but also
would deplete activated lymphocytes, including antitumor-specific
CD4 and CD8 T cells, a situation that might facilitate tumor
growth (14). For these reasons, depletion of CD25 cells should
probably be reserved to de novo vaccination under conditions of
great caution.
When the antitumor efficacy after immunization with AH1 alone
is compared with that attained after coimmunization with AH1 and
Th peptide p320–333, under different levels of depletion of
CD25 T reg cells, it is clear that Th cells play an important role
to overcome the suppressive effect of CD25 T reg cells. Thus, we
have found that the protective effect of vaccinating with AH1 alone
requires total depletion of CD25 cells previous to immunization
with AH1, and is very inefficient (0% protection) in the presence
of as low as a 4.5% of total CD25 cells. However, coimmuniza-
tion of AH1 and p320–333 allows total protection under both con-
ditions, and reaches a considerable long-lasting protective re-
sponse (33%) even in the presence of a 66.2% of total CD25 T
reg cells. To our knowledge, our results describe for the first time
that Th cells may play an important role in overcoming the sup-
pressive effect of CD25 T reg on the induction of cellular im-
mune responses. These results might be of great relevance when
developing strategies of vaccination against cancer.
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